SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Magainin Pharm (MAGN)
MAGN 8.810-2.9%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (184)6/18/1999 7:20:00 PM
From: BulbaMan  Read Replies (1) of 233
 
FDA approval of MAGN's Locilex may be helped by Pfizer's Trovan troubles. Trovan was being prescribed for diabetic foot ulcers and, given the recent warning on its safety problems, the FDA may have more incentive to provide the topical alternative of Locilex.
IMHO, at $1.75, MAGN's stock price assumes zero probability of Locilex approval. However, I think the chances are even greater than the 10-15% posted earlier.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News